Which disease will GPT-4b micro be used in clinical trials for by 2027?
Diabetes • 25%
Cancer • 25%
Cardiovascular Disease • 25%
Neurodegenerative Diseases • 25%
Clinical trial registries or publications
OpenAI's GPT-4b Micro Model Aims to Extend Life by 10 Years with Yamanaka Factors
Jan 17, 2025, 11:50 PM
OpenAI has developed a new AI model named GPT-4b micro in collaboration with Retro Biosciences, a longevity science startup, aimed at extending human lifespan by up to 10 years. The model focuses on engineering proteins, specifically the Yamanaka factors, which can transform adult human skin cells into stem cells. Preliminary tests suggest that the redesigned proteins are more than 50 times as effective as their natural counterparts in this cellular reprogramming process. This project marks OpenAI's first foray into biological data and scientific discovery, with the potential to revolutionize regenerative medicine and organ development. The collaboration was initiated a year ago, with Retro Biosciences being backed by a $180 million investment from Sam Altman, OpenAI's CEO. The model differs from Google's AlphaFold, which predicts protein structures, by focusing on protein interactions and function enhancement.
View original story
Cellular reprogramming • 25%
Genetic modification • 25%
Drug discovery • 25%
Other • 25%
Anti-aging treatments • 25%
Cellular rejuvenation • 25%
Disease prevention • 25%
Other • 25%
Stem cell therapy • 25%
Cancer research • 25%
Longevity research • 25%
Neurodegenerative diseases • 25%
Anti-Aging Treatments • 25%
Regenerative Medicine • 25%
Cancer Therapy • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
USA • 25%
Other • 25%
EU • 25%
China • 25%
Energy • 25%
Other • 25%
Healthcare • 25%
Agriculture • 25%
Yes • 50%
No • 50%
Stem Cell Therapy • 25%
Organ Regeneration • 25%
Other • 25%
Tissue Repair • 25%